2.93
Jasper Therapeutics Inc stock is traded at $2.93, with a volume of 171.74K.
It is down -0.68% in the last 24 hours and down -6.98% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
See More
Previous Close:
$2.95
Open:
$2.96
24h Volume:
171.74K
Relative Volume:
0.27
Market Cap:
$47.62M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-0.4737
EPS:
-6.1852
Net Cash Flow:
$-52.33M
1W Performance:
-5.79%
1M Performance:
-6.98%
6M Performance:
-50.84%
1Y Performance:
-83.87%
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
JSPR
Jasper Therapeutics Inc
|
2.93 | 47.62M | 0 | -64.47M | -52.33M | -6.1852 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-08-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jul-07-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jul-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Feb-13-25 | Initiated | UBS | Buy |
Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
Jul-08-24 | Initiated | BTIG Research | Buy |
Jun-27-24 | Initiated | Stifel | Buy |
May-06-24 | Initiated | H.C. Wainwright | Buy |
Apr-03-24 | Initiated | Evercore ISI | Outperform |
Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
Mar-18-24 | Initiated | TD Cowen | Outperform |
Aug-11-23 | Initiated | CapitalOne | Overweight |
Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
Nov-08-21 | Initiated | Credit Suisse | Outperform |
Oct-21-21 | Initiated | William Blair | Outperform |
Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures - MSN
HC Wainwright Issues Pessimistic Outlook for JSPR Earnings - Defense World
Q3 EPS Forecast for Jasper Therapeutics Reduced by Analyst - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
UBS Group Issues Pessimistic Forecast for Jasper Therapeutics (NASDAQ:JSPR) Stock Price - Defense World
Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $29.75 - Defense World
UBS Cuts Price Target on Jasper Therapeutics to $25 From $29, Maintains Buy Rating - MarketScreener
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $12 to $25 - 富途牛牛
Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline - TipRanks
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays, Competitive Pressures - AInvest
Jasper Therapeutics' Promising Clinical Data and Strategic Focus Earn Buy Rating - AInvest
Jasper Therapeutics’ SWOT analysis: briquilimab’s promise amid setbacks By Investing.com - Investing.com India
Jasper Therapeutics’ SWOT analysis: briquilimab’s promise amid setbacks - Investing.com
Jasper Therapeutics Reports Promising Q2 2025 Results - MSN
BTIG reiterates Buy rating on Jasper Therapeutics stock with $20 price target - Investing.com Canada
JMP reiterates Market Outperform rating on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Jasper Reports Wider Loss in Fiscal Q2 - AOL.com
Jasper Therapeutics shares fall 4.65% after-hours following Q2 2025 earnings report. - AInvest
Jasper Reports Wider Loss in Fiscal Q2 - The Motley Fool
Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33) - TipRanks
Assessing Jasper Therapeutics' Earnings Miss and Clinical Pipeline Momentum in a High-Risk, High-Reward Biotech Play - AInvest
Jasper Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jasper Therapeutics shares rise 3.51% intraday after Metagenomi reported positive business updates and financial results. - AInvest
Jasper Therapeutics under investigation for alleged securities fraud. - AInvest
Jasper Therapeutics shares rise 5.70% intraday after Metagenomi appoints Laurence Reid, PhD to its Board of Directors. - AInvest
Jasper Therapeutics Inc (JSPR) Stock: The Story of a 52-Week Stock Range - investchronicle.com
How does the Q2 2025 earnings report affect JSPR's stock price? - AInvest
Jasper Therapeutics (JSPR) Projected to Post Quarterly Earnings on Tuesday - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at EF Hutton Acquisition Co. I - 富途牛牛
Jasper Therapeutics WRT JSPRW Q2 2025 Earnings Preview Downside Expected Amid Technical Integration Hurdles - AInvest
Jasper Therapeutics JSPR 2025Q2 Earnings Preview Downside Ahead on Technical Challenges and Report Compilation Errors - AInvest
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
Jasper Therapeutics Inc expected to post a loss of $1.33 a shareEarnings Preview - TradingView
Jasper Therapeutics shares fall 3.02% intraday after Pomerantz Law Firm investigates claims of securities fraud. - AInvest
What is the risk reward ratio of investing in Jasper Therapeutics Inc. Equity Warrant stockBest Dividend Data Feed Backed By Experts - Jammu Links News
What are the latest earnings results for Jasper Therapeutics Inc.Smart Portfolio Planner With Proven Results - Jammu Links News
Press Release: Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
What catalysts could drive Jasper Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - Jammu Links News
What are the technical indicators suggesting about Jasper Therapeutics Inc. Equity WarrantStock Strategy Review For Beginners - Jammu Links News
What is the dividend policy of Jasper Therapeutics Inc. Equity Warrant stockGet ahead with breakthrough trading ideas - Jammu Links News
What is Jasper Therapeutics Inc. company’s growth strategyPre Market Picks With High Returns - jammulinksnews.com
Should I hold or sell Jasper Therapeutics Inc. Equity Warrant stock in 2025Top Growth Alerts With Proven Results - Jammu Links News
What makes Jasper Therapeutics Inc. stock price move sharplyPost Market Picks With Low Risk - Jammu Links News
How does Jasper Therapeutics Inc. Equity Warrant generate profit in a changing economySmart Portfolio Signals To Watch Now - jammulinksnews.com
Is Jasper Therapeutics Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert help - Jammu Links News
What is the risk reward ratio of investing in Jasper Therapeutics Inc. stockCapitalize on market trends early - Jammu Links News
What are Jasper Therapeutics Inc. Equity Warrant company’s key revenue driversRapidly expanding wealth - Jammu Links News
Should I hold or sell Jasper Therapeutics Inc. stock in 2025Free Stock Selection - Jammu Links News
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Jasper Therapeutics Inc Stock (JSPR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Sale |
22.11 |
900 |
19,899 |
25,009 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):